Raymond James & Associates Ginkgo Bioworks Holdings, Inc. Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

A detailed history of Raymond James & Associates transactions in Ginkgo Bioworks Holdings, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 178,358 shares of DNA stock, worth $60,641. This represents 0.0% of its overall portfolio holdings.

Number of Shares

178,358

Previous 179,670 0.73%

Holding current value

$60,641

Previous $303,000 32.01%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$1.06 - $1.67 $1,390 - $2,191	-1,312 Reduced 0.73%	178,358 $206,000
Q4 2023 Jan 16, 2024	SELL	$1.26 - $1.79 $17,537 - $24,915	-13,919 Reduced 7.19%	179,670 $303,000
Q3 2023 Oct 24, 2023	BUY	$1.61 - $2.54 $13,612 - $21,475	8,455 Added 4.57%	193,589 $350,000
Q2 2023 Jul 25, 2023	BUY	$1.14 - $1.95 $11,869 - $20,303	10,412 Added 5.96%	185,134 $344,000
Q1 2023 Apr 14, 2023	BUY	$1.2 - $2.19 $9,652 - $17,616	8,044 Added 4.83%	174,722 $232,000

Q4 2022 Feb 08, 2023	SELL	$1.63 - $3.52 $20,314 - $43,869	-12,463 Reduced 6.96%	166,678 $281,000
Q3 2022 Oct 25, 2022	BUY	$0.73 - $3.74 $42,802 - $219,291	58,634 Added 48.66%	179,141 $559,000
Q2 2022 Aug 12, 2022	BUY	$2.2 - $4.2 $69,495 - $132,673	31,589 Added 35.53%	120,507 $287,000
Q1 2022 May 11, 2022	BUY	$2.83 - $8.69 $188,647 - $579,275	66,660 Added 299.49%	88,918 $358,000
Q4 2021 Feb 08, 2022	SELL	$8.31 - $14.92 $218,237 - $391,829	-26,262 Reduced 54.13%	22,258 $185,000
Q3 2021 Nov 02, 2021	BUY	$9.15 - $13.28 $443,958 - $644,345	48,520 New	48,520 $562,000

Others Institutions Holding DNA

# of Institutions

359

Shares Held

1.26B

Call Options Held

845K

Put Options Held

2.54M

View Full List

About Ginkgo Bioworks Holdings, Inc.

Ticker DNA
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 1,287,779,968
Market Cap $438M
Description
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...

More about DNA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Ginkgo Bioworks Holdings, Inc. Transaction History